Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Gross Margin (2016 - 2025)

Historic Gross Margin for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to 87.38%.

  • United Therapeutics' Gross Margin fell 15200.0% to 87.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 116.47%, marking a year-over-year increase of 306900.0%. This contributed to the annual value of 89.24% for FY2024, which is 3000.0% up from last year.
  • As of Q3 2025, United Therapeutics' Gross Margin stood at 87.38%, which was down 15200.0% from 89.03% recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Gross Margin peaked at 94.39% during Q1 2022, and registered a low of 7000.0% during Q4 2023.
  • For the 5-year period, United Therapeutics' Gross Margin averaged around 303.37%, with its median value being 89.25% (2023).
  • Its Gross Margin has fluctuated over the past 5 years, first soared by 19700bps in 2022, then tumbled by -70880400bps in 2023.
  • United Therapeutics' Gross Margin (Quarter) stood at 91.67% in 2021, then decreased by -4bps to 88.04% in 2022, then plummeted by -8051bps to 7000.0% in 2023, then surged by 101bps to 88.9% in 2024, then decreased by -2bps to 87.38% in 2025.
  • Its Gross Margin stands at 87.38% for Q3 2025, versus 89.03% for Q2 2025 and 88.36% for Q1 2025.